$ERYP News
Last published 3y ago
- 3y agoERYPERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023GlobeNewswireERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023 All resolutions voted with a large majority according to
- 3y agoERYPERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuitGlobeNewswireERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (NASDAQ:ERYP) announces the filing
- 3y agoERYPErytech Pharma SA (ERYP) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
- 4y agoERYPPARIS:ERYPERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendarGlobeNewswireERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar Cambridge, MA (U.S.) and Lyon (France), April 28, 2022 – ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage
- 4y agoARDXBBAIERYPNKTX+1Thinking about buying stock in ToughBuilt Industries, Ardelyx, Nkarta, Erytech Pharma, or BigBear.ai?PR NewswireNEW YORK, April 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, ARDX, NKTX, ERYP, and BBAI.
- 4y agoERYPPARIS:ERYPERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with CatalentGlobeNewswireERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent Catalent acquired ERYTECH's U.S. cell therapy manufacturing facility for a total consideration of USD 44.5 million ERYTECH and Cat
- 4y agoAMTXCDKERYPEURN+1Thinking about buying stock in Vyne Therapeutics, Erytech Pharma, CDK Global, Euronav NV, or Aemetis?PR NewswireNEW YORK, April 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VYNE, ERYP, CDK, EURN, and AMTX. T
- 4y agoERYPPARIS:ERYPERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic DiseasesGlobeNewswireERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases Cambridge, MA (U.S.) and Lyon (France), February 8, 2022 – ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
- 5y agoERYPERYTECH Announces the Availability of its Half-Year Financial Report 2021GlobeNewswireERYTECH Announces the Availabilityof its Half-Year Financial Report 2021 Lyon (France) and Cambridge, MA (U.S.), Septembre 22, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therap
- 5y agoERYPERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021GlobeNewswireERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021 Conference call and webcast on Tuesday, September 21, 2021at 8:30am EDT / 2:30pm CET TRYbeCA-1 Phase 3 trial of eryaspase in second
- 5y agoERYPERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business UpdateGlobeNewswireERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update Lyon (France) and Cambridge, MA (U.S.), September 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company d
- 5y agoERYPERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Cambridge, MA (U.S.) and Lyon (France), September 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innova
- 5y agoERYPERYTECH to Participate in the Citi 16th Annual BioPharma ConferenceGlobeNewswireERYTECH to Participate in the Citi 16th Annual BioPharma Conference Cambridge, MA (U.S.) and Lyon (France), August 30, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
- 5y agoERYPERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic CancerGlobeNewswireERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer Webinar on Wednesday, September 1st @ 10am ET/4pm CET Cambridge, MA (U.S.) and Lyon (France), August 24, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-
- 5y agoERYPNERVNVTAPKI+2Papyrus Therapeutics Inc. Announces Additions to Its Board of DirectorsBusiness WirePapyrus Therapeutics Inc. is delighted to announce that two new members have joined our Board of Directors, Marc Beer as chairman and Professor James Lorens PhD as an independent director. Marc brings more then 30 years of therapeutic development and
- 5y agoAFRMAUTLERYPINFI+1Thinking about buying stock in Infinity Pharmaceuticals, Autolus Therapeutics, Affirm Holdings, Erytech Pharma, or Exela Technologies?PR NewswireNEW YORK, Aug. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INFI, AUTL, AFRM, ERYP, and XELA. T
- 5y agoAHPIATOSCEIERYP+1Thinking about buying stock in Erytech Pharma, NanoVibronix, Atossa Therapeutics, Allied Healthcare, or Camber Energy?PR NewswireNEW YORK, July 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ERYP, NAOV, ATOS, AHPI, and CEI. T
- 5y agoERYPERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALLGlobeNewswireERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL Fast Track designation for eryaspase underscores the need for new treatment options for patients who developed hypersensitivity reactions to pegylated asparaginas
- 5y agoERYPERYTECH to Participate in the BTIG Virtual Biotechnology ConferenceGlobeNewswireERYTECH to Participate in the BTIG Virtual Biotechnology Conference Cambridge, MA (U.S.) and Lyon (France), July 27, 2021 –ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by en
- 5y agoERYPERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL PatientsGlobeNewswireERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients Meeting with the U.S. FDA clarified steps and requirements for the submission of a Biologics License Application (BLA) for eryaspase for the treatment of ALL patients w
- 5y agoERYPReport - Erytech's Combined Shareholders' Meeting on June 25, 2021GlobeNewswireREPORT - ERYTECH'S COMBINED SHAREHOLDERS' MEETING ON JUNE 25, 2021 SS RELEASE Lyon (France), June 25, 2021 – ERYTECH Pharma (NASDAQ:ERYP) announced that its 2021 Annual General Meeting was held in Lyon on Friday, Jun
- 5y agoERYPERYTECH to Participate in Upcoming Virtual Investor Conferences in JuneGlobeNewswireERYTECH to Participate in Upcoming Virtual Investor Conferences in June Lyon (France) and Cambridge, MA (U.S.), May 26, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies b
- 5y agoERYPErytech's Combined Shareholders' Meeting on June 25, 2021GlobeNewswireERYTECH'S COMBINED SHAREHOLDERS' MEETING ON JUNE 25, 2021Live webcast of the Shareholders' Meeting Availability of the preparatory documents for the Shareholders' Meeting SS RELEASE Lyon (France), May 25, 2020 – E
- 5y agoERYPERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021GlobeNewswireERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021 Conference call and webcast on Wednesday, May 5, 2021at 8:30am EST/ 2:30pm CET TRYbeCA-1, Phase 3 clinical trial in 2nd line pancreatic
- 5y agoERYPERYTECH Announces $30.0 Million Registered Direct OfferingGlobeNewswireERYTECH Announces $30.0 Million Registered Direct Offering Lyon (France) and Cambridge, MA (U.S.), April 29, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP) (the "Company"), a clinical-stage biopharmaceutical company developing innovative thera
- 5y agoERYPERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 conference callGlobeNewswireERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 conference call Publication of Q1 2021 results on 4 May 2021 after market close Lyon (France) and Cambridge, MA (U.S.), April 29, 2021 – ERYTECH Pharma (N
- 5y agoERYPERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALLGlobeNewswireERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL ERYTECH invited by FDA to request a pre-BLA meeting First step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive AL
- 5y agoERYPERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic CancerGlobeNewswireERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer No dose-limiting toxicity reported in the first dose cohort Encouraging clinical activity observed in first patients
- 5y agoERYPERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic CancerGlobeNewswireA total of 510 patients enrolledEvents required to trigger interim superiority analysis accruedInterim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and...
- 5y agoERYPERYTECH to Present at the JMP Securities Hematology SummitGlobeNewswireLYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by...
- 5y agoERYPMonthly information related to total number of voting rights and shares composing the share capital – November 30, 2020GlobeNewswireLYON, France, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market...
- 5y agoERYPERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual MeetingGlobeNewswireWebcast today, Monday, December 7at 4:00 pm CET/10:00 am ET The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase ...
- 5y agoERYPERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American Society of Hematology 2020 Annual MeetingGlobeNewswireLYON, France and CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by...
- 6y agoERYPERYTECH to Present at Jefferies Virtual Healthcare ConferenceGlobeNewswireLYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced today that its CEO, Gil Beyen, will present an update at the Jefferies...
- 6y agoERYPERYTECH Pharma's (ERYP) CEO Gil Beyen on Q3 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoERYPERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020GlobeNewswireConference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer: More than 95% of the approximately 500 patients...
- 6y agoERYPERYTECH Announces Abstract with Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Selected for Oral Presentation at the American Society of Hematology 2020 Annual MeetingGlobeNewswireOral presentation to discuss findings from the Nordic Society of Paediatric Haematology and Oncology (NOPHO)-sponsored Phase 2 trial that confirm the potential of eryaspase as a treatment option for...
- 6y agoERYPMonthly information related to total number of voting rights and shares composing the share capital – October 31, 2020.GlobeNewswireArticle 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -...
- 6y agoERYPERYTECH Secures €10 Million in Non-Dilutive Financing, Guaranteed by the French GovernmentGlobeNewswireApprovals received from Bpifrance and Société Générale for a total of EUR 10 million in non-dilutive financing in the form of a State-Guaranteed Loan (PGE Loan)Proceeds expected to extend Company’s...
- 6y agoERYPERYTECH to Host Third Quarter 2020 Conference Call and Business Update on November 6, 2020GlobeNewswireLYON, France, Oct. 29, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...
- 6y agoERYPERYTECH Appoints Stewart Craig as Chief Technical OfficerGlobeNewswireLYON, France and CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by...
- 6y agoONCYINCYERYPOCX+1Clinical Trials Delivering New Optimism in Fight Against Triple-Negative Breast CancerPR NewswireUSA News Group – It's been a year and a half since the US Food and Drug Administration approved the first targeted immunotherapy in the treatment of...
- 6y agoERYPMonthly information related to total number of voting rights and shares composing the share capital - September 30, 2020GlobeNewswireArticle 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C...
- 6y agoERYPERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020GlobeNewswireTRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer: More than 90% of the planned 500 patients enrolled Fast-Track designation granted by U.S. FDAInterim superiority analysis expected...
- 6y agoERYPERYTECH establishes a financing facility with the implementation of an at-the-market program on Nasdaq with CowenGlobeNewswireLYON, France, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...
- 6y agoERYPERYTECH to Host on September 22, 2020 Second Quarter 2020 Conference Call and Business UpdateGlobeNewswireLYON, France, Sept. 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...
- 6y agoERYPERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete EnrollmentGlobeNewswireMore than 450 of the planned ~500 patients enrolled Interim superiority analysis expected around year-end 2020Call with KOL Dr. Manuel Hidalgo on September 29, 2020 at 10:00 am ET LYON, France and...
- 6y agoERYPMonthly information related to total number of voting rights and shares composing the share capital – August 31, 2020GlobeNewswireLYON, France, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market...
- 6y agoERYPMonthly information related to total number of voting rights and shares composing the share capital – July 31, 2020GlobeNewswireLYON, France, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext...
- 6y agoERYPERYTECH Reports Voting Results from its Annual General Meeting Held on June 26, 2020GlobeNewswireLYON, France and CAMBRIDGE, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2020 Annual General Meeting was held in Lyon on Friday, June...